Phathom Pharmaceuticals Inc Ordinary shares PHAT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHAT is a good fit for your portfolio.
News
-
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
-
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
-
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
-
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment
Trading Information
- Previous Close Price
- $9.10
- Day Range
- $8.96–9.43
- 52-Week Range
- $6.07–17.02
- Bid/Ask
- $9.18 / $9.19
- Market Cap
- $537.25 Mil
- Volume/Avg
- 370,890 / 918,572
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 684.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 112
- Website
- https://www.phathompharma.com
Comparables
Valuation
|
Metric
|
PHAT
|
AVIR
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.56 | 3.30 |
Price/Sales | 684.36 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PHAT
AVIR
ICVX
Financial Strength
|
Metric
|
PHAT
|
AVIR
|
ICVX
|
|---|---|---|---|
Quick Ratio | 9.88 | 17.86 | 17.59 |
Current Ratio | 10.25 | 18.24 | 18.06 |
Interest Coverage | −3.99 | — | — |
Quick Ratio
PHAT
AVIR
ICVX
Profitability
|
Metric
|
PHAT
|
AVIR
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −63.92% | −15.46% | −29.30% |
Return on Equity (Normalized) | — | −16.16% | −31.87% |
Return on Invested Capital (Normalized) | −206.62% | −19.92% | −34.69% |
Return on Assets
PHAT
AVIR
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwwbswyxs | Gqq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mnvllkqm | Hwkhz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jwwrfbym | Wzgxhwr | $97.8 Bil | |
MRNA
| Moderna Inc | Zftgddc | Lvdcm | $38.8 Bil | |
ARGX
| argenx SE ADR | Fkpskdlx | Rnypg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gnhnpdcc | Znpvx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lgqkwmwk | Qmgrtw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hkjzxdrr | Hdpzzt | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lmyvfcznz | Kvsrrl | $12.5 Bil | |
INCY
| Incyte Corp | Hfqndczqf | Yxqvwsm | $11.5 Bil |